Relay Therapeutics Expands Clinical Leadership Team with Addition of Tara O’Meara and Charles Ferté
03 mai 2021 06h00 HE
|
Relay Therapeutics, Inc.
CAMBRIDGE, Mass., May 03, 2021 (GLOBE NEWSWIRE) -- Relay Therapeutics, Inc. (Nasdaq: RLAY), a clinical-stage precision medicine company transforming the drug discovery process by combining leading...
Relay Therapeutics Extends Leadership in Integrating Computational and Experimental Approaches to Create Precision Medicines by Acquiring ZebiAI
16 avr. 2021 06h00 HE
|
Relay Therapeutics, Inc.
Relay Therapeutics’ leadership in this new breed of biotech positions the company as a strategic partner of choice for emerging technologies and founders in these fields ZebiAI amplifies Relay...
Relay Therapeutics Reports Fourth Quarter and Full Year 2020 Financial Results and Operational Highlights
25 mars 2021 16h05 HE
|
Relay Therapeutics, Inc.
Advanced two programs, RLY-1971 and RLY-4008, into clinical development, and on track to initiate IND enabling studies with PI3Kα mutant selective inhibitor in 2021 Entered into a global...
Relay Therapeutics to Present Preclinical Data on RLY-4008 at AACR Annual Meeting
10 mars 2021 16h30 HE
|
Relay Therapeutics, Inc.
CAMBRIDGE, Mass., March 10, 2021 (GLOBE NEWSWIRE) -- Relay Therapeutics, Inc. (Nasdaq: RLAY), a clinical-stage precision medicine company transforming the drug discovery process by leveraging...
Relay Therapeutics to Participate in Fireside Chat at Guggenheim Healthcare Talks 2021 Oncology Day
04 févr. 2021 16h05 HE
|
Relay Therapeutics, Inc.
CAMBRIDGE, Mass., Feb. 04, 2021 (GLOBE NEWSWIRE) -- Relay Therapeutics, Inc. (Nasdaq: RLAY) is scheduled to participate in a fireside chat at the Guggenheim Healthcare Talks 2021 Oncology Day on...
Relay Therapeutics to Present at 39th Annual J.P. Morgan Healthcare Conference
06 janv. 2021 06h00 HE
|
Relay Therapeutics, Inc.
CAMBRIDGE, Mass., Jan. 06, 2021 (GLOBE NEWSWIRE) -- Relay Therapeutics, Inc. (Nasdaq: RLAY) is scheduled to present at the 39th Annual J.P. Morgan Healthcare Conference on Tuesday, January 12, 2021...
Relay Therapeutics Announces a Worldwide License and Collaboration Agreement with Genentech for RLY-1971
14 déc. 2020 06h00 HE
|
Relay Therapeutics, Inc.
Collaboration brings together clinical stage SHP2 and KRAS G12C inhibitors Relay Therapeutics will receive $75 million upfront and is eligible to receive an additional $25 million in near-term...
Relay Therapeutics Reports Third Quarter 2020 Financial Results
12 nov. 2020 16h05 HE
|
Relay Therapeutics, Inc.
CAMBRIDGE, Mass., Nov. 12, 2020 (GLOBE NEWSWIRE) -- Relay Therapeutics, Inc. (Nasdaq: RLAY), a clinical-stage precision medicine company transforming the drug discovery process by leveraging...
Relay Therapeutics Announces Dosing of First Patient in First-in-Human Clinical Trial of RLY-4008, a Highly Selective FGFR2 Inhibitor
03 sept. 2020 16h05 HE
|
Relay Therapeutics, Inc.
CAMBRIDGE, Mass., Sept. 03, 2020 (GLOBE NEWSWIRE) -- Relay Therapeutics, Inc. (Nasdaq: RLAY), a clinical-stage precision medicine company transforming the drug discovery process by leveraging...
Relay Therapeutics Reports Second Quarter 2020 Financial Results
27 août 2020 06h50 HE
|
Relay Therapeutics, Inc.
CAMBRIDGE, Mass., Aug. 27, 2020 (GLOBE NEWSWIRE) -- Relay Therapeutics, Inc. (Nasdaq: RLAY), a clinical-stage precision medicine company transforming the drug discovery process by leveraging...